Search Result

Results for "

bladder cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Aldose Reductase (1) Androgen Receptor (1) Apoptosis (21) Autophagy (8) Bacterial (2) Bcl-2 Family (3) c-Met/HGFR (2) c-Myc (2) Casein Kinase (1) Drug Metabolite (1) Endogenous Metabolite (1) FAK (1) Ferroptosis (4) FGFR (3) Fungal (1) HDAC (1) Histone Methyltransferase (3) HIV (1) HSP (2) HSV (1) Isotope-Labeled Compounds (1) JNK (2) MAP4K (1) Microtubule/Tubulin (2) mTOR (1) nAChR (1) NO Synthase (1) Parasite (1) Potassium Channel (1) PPAR (5) PROTACs (3) RANKL/RANK (1) Reactive Oxygen Species (1) Toll-like Receptor (TLR) (1) Topoisomerase (1) TRP Channel (2) VEGFR (1)
By Research Areas:	Cancer (50) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (4)

By Targets:

Akt (2)

Aldose Reductase (1)

Androgen Receptor (1)

Apoptosis (21)

Autophagy (8)

Bacterial (2)

Bcl-2 Family (3)

c-Met/HGFR (2)

c-Myc (2)

Casein Kinase (1)

Drug Metabolite (1)

Endogenous Metabolite (1)

FAK (1)

Ferroptosis (4)

FGFR (3)

Fungal (1)

HDAC (1)

Histone Methyltransferase (3)

HIV (1)

HSP (2)

HSV (1)

Isotope-Labeled Compounds (1)

JNK (2)

MAP4K (1)

Microtubule/Tubulin (2)

mTOR (1)

nAChR (1)

NO Synthase (1)

Parasite (1)

Potassium Channel (1)

PPAR (5)

PROTACs (3)

RANKL/RANK (1)

Reactive Oxygen Species (1)

Toll-like Receptor (TLR) (1)

Topoisomerase (1)

TRP Channel (2)

VEGFR (1)

By Research Areas:

Cancer (50)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (6)

Metabolic Disease (2)

Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145944

ASR-488

Apoptosis Cancer

ASR-488 activates the mRNA-binding protein CPEB1, induces apoptosis and inhibits bladder cancer growth .

ASR-488	Apoptosis	Cancer
ASR-488 activates the mRNA-binding protein CPEB1, induces apoptosis and inhibits bladder cancer growth .

HY-115718A

PZ703b TFA 1 Publications Verification	PROTACs Bcl-2 Family	Cancer
PZ703b TFA is a Bcl-xl PROTAC degradation agent that induces apoptosis and inhibits cancer cell proliferation for bladder cancer research .

HY-160188

BAY-9683	PPAR	Cancer
BAY-9683 is an orally active covalent PPARG inverse agonist. BAY-9683 can be used in the study of diseases with overactive PPARG, such as luminal bladder cancer .

HY-147714

FGFR3-IN-2	FGFR VEGFR	Cancer
FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor, with IC₅₀s of 4.1 nM and 570 nM for FGFR3 and VEGFR2, respectively. FGFR3-IN-2 can be used for the research of bladder cancer .

HY-147713

FGFR3-IN-1	FGFR	Cancer
FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor, with IC₅₀s of 40 nM, 5.1 nM, and 12 nM for FGFR1, 2, and 3, respectively. FGFR3-IN-1 can be used for the research of bladder cancer .

HY-147715

FGFR3-IN-3	FGFR	Cancer
FGFR3-IN-3 (compound 40a) is a potent and pan-FGFR inhibitor, with IC₅₀s of 2.1 nM, 3.1 nM, 4.3 nM and 74 nM for FGFR1, 2, 3, and 4, respectively. FGFR3-IN-3 can be used for the research of bladder cancer .

HY-115718

PZ703b 1 Publications Verification	PROTACs Bcl-2 Family	Cancer
PZ703b is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b can be used for the research of bladder cancer research .

HY-115718B

PZ703b hydrochloride 1 Publications Verification	PROTACs Apoptosis Bcl-2 Family	Cancer
PZ703b hydrochloride is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b hydrochloride can be used for the research of bladder cancer research .

HY-108932A

Gemcitabine monophosphate disodium Gemcitabine 5′-phosphate disodium	Apoptosis	Cancer
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) disodium can be used to synthesis nanoparticles. Gemcitabine monophosphate disodium is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate disodium can be used for bladder cancer research .

HY-W010482S

3-Ethylaniline-d5	Isotope-Labeled Compounds	Cancer
3-Ethylaniline-d₅ is the deuterium labeled 3-Ethylaniline (HY-W010482). 3-Ethylaniline is metabolized in vivo to electrophilic intermediates that covalently bind to DNA and that adducts are formed in the DNA of bladder. 3-Ethylaniline can be used for the research of bladder cancer[1][2].

HY-N7707

Sandacanol

Apoptosis Cancer

Sandacanol is a specific agonist of olfactory receptor (OR10H1). Sandacanol induces cell cycle arrest and some apoptosis in bladder cancer cells .

Sandacanol	Apoptosis	Cancer
Sandacanol is a specific agonist of olfactory receptor (OR10H1). Sandacanol induces cell cycle arrest and some apoptosis in bladder cancer cells .

HY-163323

AKR1C3-IN-12	Aldose Reductase	Cancer
AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer .

HY-126566

Trichostatin C	Fungal HDAC Apoptosis	Infection Cancer
Trichostatin C is an inhibitor for histone deacetylase (HDAC), induces apoptosis and arrests cell cycle at G2/M phase, and exhibits anticancer activity against lung cancer and urothelial bladder cancer . Trichostatin C induces differentation of Friend leukemic cells . Trichostatin C exhibits antifungal activity .

HY-13299

MK-8033 2 Publications Verification	c-Met/HGFR	Cancer
MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .

HY-13299A

MK-8033 hydrochloride 2 Publications Verification	c-Met/HGFR	Cancer
MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .

HY-149292

SR-4133	Casein Kinase	Cancer
SR-4133 is a potent and highly CK1ε selective inhibitor with an IC₅₀ of 58 nM. SR-4133 binds to the ATP-binding site of CK1ε. SR-4133 displays nanomolar growth inhibition of bladder cancer cells, and inhibits the phosphorylation of 4E-BP1 .

HY-146406

Anticancer agent 52	Apoptosis	Cancer
Anticancer agent 52 is a potent anticancer agent. Anticancer agent 52 shows in vitro cytotoxicity. Anticancer agent 52 induces apoptosis. Anticancer agent 52 shows antitumor effect. Anticancer agent 52 has the potential for the research of bladder cancer .

HY-N2420

Flavokawain A 1 Publications Verification	Apoptosis	Cancer
Flavokawain A, a proming anticarcinogenic agent, is a chalcone from kava extract with anti-tumor activity. Flavokawain A induces cell apoptosis by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway. Flavokawain A has the potential for the study of bladder cancer .

HY-161341

β-Glucuronidase responsive conjugate 1	Others	Cancer
β-Glucuronidase responsive conjugate 1 (compound 3) is a well-balanced photosensitizer which has photodynamic activity. β-Glucuronidase responsive conjugate 1 inhibits T-24 cell viability and growth with an IC₅₀ of 0.2 μM. β-Glucuronidase responsive conjugate 1 can used to study bladder cancers .

HY-149035

PAA4	Others	Cancer
PAA4 is a methide carbon-centered polynuclear Au(I) clusters. PAA4 shows antiproliferative activity. PAA4 increases the expression of pH2AX in a time dependent manner. PAA4 shows anti-tumor effect in orthotopic bladder cancer mouse model .

HY-124805

MAL3-101	HSP	Cancer
MAL3-101 is a potent HSP70 allosteric inhibitor. MAL3-101 inhibits HSP70 ATPase activity by blocking Hsp40 co-chaperone interaction. MAL3-101 can be used for researching muscle invasive bladder cancer (MIBC) .

HY-119198

NSC745885	Apoptosis Histone Methyltransferase	Cancer
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers .

HY-N6973

Boldine	RANKL/RANK Apoptosis	Inflammation/Immunology
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK signaling pathway. It can be used in rheumatoid arthritis research .

HY-16993

OICR-9429 5+ Cited Publications	Histone Methyltransferase Apoptosis	Cancer
OICR-9429 is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .

HY-118160

PPM-18 NSC 73233	NO Synthase	Inflammation/Immunology Cancer
PPM-18 (NSC 73233), a potent anti-inflammatory agent, inhibits nitric oxide synthase expression. PPM-18 is a potent inhibitor of iNOS expression by blocking the binding of NF-κB to promoter . PPM-18, an analog of Vitamin K, induces autophagy and apoptosis in bladder cancer cells through ROS and AMPK signaling pathways .

HY-151137

HSP90/mTOR-IN-1	mTOR HSP Apoptosis Autophagy	Cancer
HSP90/mTOR-IN-1 is a potent and orally active Hsp90 and mTOR inhibitor with IC₅₀ values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the PI3K/AKT/mTOR pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer .

HY-113636

Kazinol A

Others Cancer

Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2 .

Kazinol A	Others	Cancer
Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2 .

HY-N0800

Protosappanin B (-)-Protosappanin B	Apoptosis	Cancer
Protosappanin B is a phenolic compound extracted from Caesalpinia sappan. Anti-cancer activity . Protosappanin B induces apoptosis and causes G₁ cell cycle arrest in human bladder cancer cells .

HY-160161

BAY-5094

PPAR Cancer

BAY-5094 is a PPAR gamma (PPARG) inverse agonist. BAY-5094 has oral activity. BAY-5094 can be used in the research of luminal bladder cancer .

BAY-5094	PPAR	Cancer
BAY-5094 is a PPAR gamma (PPARG) inverse agonist. BAY-5094 has oral activity. BAY-5094 can be used in the research of luminal bladder cancer .

HY-12703

KSI-3716 1 Publications Verification	c-Myc Autophagy	Cancer
KSI-3716 is a potent c-Myc inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer .

HY-N2593

Isorhapontigenin 1 Publications Verification	Autophagy	Inflammation/Immunology Cancer
Isorhapontigenin, an orally bioavailable dietary polyphenol isolated from the Chinese herb Gnetum cleistostachyum, displays anti-inflammatory effects. Isorhapontigenin induces autophagy and inhibits invasive bladder cancer formation .

HY-N5106

(E)-Flavokawain A	Apoptosis	Cancer
(E)-Flavokawain A, a chalcone extracted from Kava, has anticarcinogenic effect. (E)-Flavokawain A induces apoptosis in bladder cancer cells by involvement of bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice .

HY-134990

Hematoporphyrin monomethyl ether 1 Publications Verification	Apoptosis	Cancer
Hematoporphyrin monomethyl ether, second generation of porphyrin-related photosensitizer, is characterized by its single form, high yield of singlet oxygen, high selectivity, and low toxicity, which has been widely used in the diagnosis and research of various tumors, including lung cancer, bladder cancer, and nevus flammeus and brain glioma .

HY-N6872

Actein	JNK Akt Apoptosis Autophagy	Cancer
Actein is a triterpene glycoside isolated from the rhizomes of Cimicifuga foetida. Actein suppresses cell proliferation, induces autophagy and apoptosis through promoting ROS/JNK activation, and blunting AKT pathway in human bladder cancer. Actein has little toxicity in vivo .

HY-12041

SP600125 Maximum Cited Publications 405 Publications Verification	JNK Autophagy Apoptosis Ferroptosis	Cancer
SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC₅₀s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .

HY-B0063

Gimatecan

ST1481
Topoisomerase Cancer

Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity .
HY-160160

BAY-5516

PPAR Cancer

BAY-5516 is a inverse-agonist o PPARG, with the IC₅₀ value of 6.1±3.6 nM that has anti-tumor effect .

Gimatecan ST1481	Topoisomerase	Cancer
Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity .

BAY-5516	PPAR	Cancer
BAY-5516 is a inverse-agonist o PPARG, with the IC₅₀ value of 6.1±3.6 nM that has anti-tumor effect .

HY-150510

MS8511	Histone Methyltransferase	Neurological Disease Cancer
MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC₅₀ values of 100 nM (G9a) and 140 nM (GLP), and K_d values of 44 nM (G9a) and 46 nM (GLP). MS8511 reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS) .

HY-N1372A

Fangchinoline 4 Publications Verification	HIV FAK Apoptosis Autophagy	Infection Cancer
Fangchinoline is isolated from Stephania tetrandra with extensive biological activities, such as enhancing immunity, anti-inflammatory sterilization and anti-atherosclerosis. Fangchinoline, a novel HIV-1 inhibitor, inhibits HIV-1 replication by impairing gp160 proteolytic processing . Fangchinoline targets Focal adhesion kinase (FAK) and suppresses FAK-mediated signaling pathway in tumor cells which highly expressed FAK . Fangchinoline induces apoptosis and adaptive autophagy in bladder cancer .

HY-108932

Gemcitabine monophosphate Gemcitabine 5′-phosphate	Apoptosis	Cancer
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate shows synergistic anti-cancer effects .

HY-B0567

Dequalinium Chloride	Potassium Channel nAChR Apoptosis Bacterial Parasite	Infection Cancer
Dequalinium chloride is an Apamin (HY-P0256)-sensitive potassium channel selective blocker. Dequalinium chloride is a cationic, lipophilic mitochondrial poison. Dequalinium chloride is also an antagonist pf α7 nAChR, and an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity .

HY-146358

Anticancer agent 49	Microtubule/Tubulin	Cancer
Anticancer agent 49 (compound 69) is a broad spectrum anticancer agent. Anticancer agent 49 inhibits tubulin polymerization. Anticancer agent 49 shows antiproliferative activity. Anticancer agent 49 has the potential for the research of solid and hematological tumors .

HY-149036

PAA5	Ferroptosis Endogenous Metabolite Reactive Oxygen Species	Cancer
PAA5 is a methide carbon-centered polynuclear Au(I) cluster. PAA5 can release Au(I) causing Pro-oxidant response and accelerated ferroptosis. PAA5 increases the expression of pH2AX in a time-dependent manner. PAA5 has anticancer activity .

HY-148838

c-Myc inhibitor 8	c-Myc	Cancer
c-Myc inhibitor 8 (compound 56) is a c-Myc inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research .

HY-146357

Anticancer agent 48	Microtubule/Tubulin	Cancer
Anticancer agent 48 (compound 48) is a broad spectrum anticancer agent. Anticancer agent 48 inhibits tubulin polymerization. Anticancer agent 48 shows antiproliferative activity. Anticancer agent 48 shows antitumor activity in vivo. Anticancer agent 48 has the potential for the research of solid and hematological tumors .

HY-160218

HPK1-IN-42

MAP4K Cancer

HPK1-IN-42 (compound 185) ia a HPK1 inhibitor with the IC₅₀ 50 of 0.24 nM .

HPK1-IN-42	MAP4K	Cancer
HPK1-IN-42 (compound 185) ia a HPK1 inhibitor with the IC₅₀ 50 of 0.24 nM .

HY-17386

Rosiglitazone 80+ Cited Publications BRL 49653	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-17386B

Rosiglitazone potassium BRL 49653 potassium	PPAR TRP Channel Autophagy Apoptosis Ferroptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone potassium is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone potassium can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-137605

WSF1-IN-1	Others	Cancer
WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC₅₀ values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively .

HY-110353

CU-T12-9 3 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
CU-T12-9 is a specific TLR1/2 agonist with EC₅₀ of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS .

Cat. No.	Product Name	Category	Target	Chemical Structure